Corporate ActionMay 5, 2026, 05:16 PM
Aura Biosciences Closes Public Offering, Raises $299.4M
AI Summary
Aura Biosciences, Inc. announced the closing of its previously announced underwritten public offering, generating approximately $299.4 million in gross proceeds. The offering included the sale of 46,099,650 shares of common stock, which incorporated the full exercise of the underwriters' option to purchase additional shares. Additionally, 3,800,000 pre-funded warrants were sold to certain investors. The common stock was priced at $6.00 per share, and the pre-funded warrants at $5.99999 per share.
Key Highlights
- Aura Biosciences closed its underwritten public offering, raising approximately $299.4 million in gross proceeds.
- The offering included 46,099,650 shares of common stock, with underwriters fully exercising their option.
- Additionally, 3,800,000 pre-funded warrants were sold to certain investors.
- Common stock was sold at a public offering price of $6.00 per share.
- Pre-funded warrants were sold at $5.99999 per share.
- Leerink Partners, TD Cowen, and Evercore ISI acted as joint bookrunning managers.
Price Impact
More from AURA